Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. Region Stockholm
2. Cancer Research KI
3. Swedish Cancer Society
4. Swedish Research Council
5. Roche Sweden